Sandrine Marréaud

19.5k total citations · 7 hit papers
145 papers, 7.7k citations indexed

About

Sandrine Marréaud is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Sandrine Marréaud has authored 145 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Oncology, 90 papers in Pulmonary and Respiratory Medicine and 42 papers in Surgery. Recurrent topics in Sandrine Marréaud's work include Sarcoma Diagnosis and Treatment (55 papers), Vascular Tumors and Angiosarcomas (31 papers) and Lung Cancer Treatments and Mutations (16 papers). Sandrine Marréaud is often cited by papers focused on Sarcoma Diagnosis and Treatment (55 papers), Vascular Tumors and Angiosarcomas (31 papers) and Lung Cancer Treatments and Mutations (16 papers). Sandrine Marréaud collaborates with scholars based in Belgium, France and Netherlands. Sandrine Marréaud's co-authors include Sandra Collette, Jean‐Yves Blay, Richard Sylvester, Jaap Verweij, Patrick Schöffski, Peter Hohenberger, Saskia Litière, J. Martijn Kerst, Ian Judson and Winette T.A. van der Graaf and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Sandrine Marréaud

143 papers receiving 7.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

2014 814 citations Ian Judson, Jaap Verweij et al. profile →
A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma

2010 698 citations Sandrine Marréaud, Sandra Collette et al. European Urology profile →
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

2009 535 citations Stefan Sleijfer, Isabelle Ray‐Coquard et al. Journal of Clinical Oncology profile →
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

2011 523 citations Maria De Santis, Joaquim Bellmunt et al. Journal of Clinical Oncology profile →
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial

2012 383 citations Axel Le Cesne, Sylvie Bonvalot et al. profile →
Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

2012 340 citations Jorg R. Oddens, Maurizio Brausi et al. European Urology profile →
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib

2018 306 citations Sandrine Marréaud, Sandra Collette et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandrine Marréaud Belgium	38	4.8k	3.8k	2.7k	1.6k	1.3k	145	7.7k
Jürgen Dunst Germany	45	3.0k 0.6×	1.8k 0.5×	2.4k 0.9×	770 0.5×	948 0.7×	234	6.9k
Aristotelis Bamias Greece	36	2.2k 0.5×	3.1k 0.8×	1.9k 0.7×	1.7k 1.0×	178 0.1×	276	6.9k
Jonathan E. Rosenberg United States	51	4.1k 0.9×	5.5k 1.5×	7.0k 2.6×	4.2k 2.6×	353 0.3×	404	13.5k
D. Spooner United Kingdom	30	3.4k 0.7×	3.8k 1.0×	2.1k 0.8×	725 0.4×	559 0.4×	111	6.4k
Saul E. Rivkin United States	40	2.0k 0.4×	3.6k 0.9×	971 0.4×	820 0.5×	474 0.4×	127	5.8k
Philippe Beuzeboc France	47	3.2k 0.7×	3.9k 1.0×	1.6k 0.6×	1.2k 0.7×	156 0.1×	243	7.6k
Sandy Srinivas United States	40	3.4k 0.7×	2.9k 0.8×	2.2k 0.8×	2.0k 1.2×	269 0.2×	192	6.6k
Vitaly Margulis United States	47	4.1k 0.8×	1.5k 0.4×	5.6k 2.1×	2.4k 1.5×	236 0.2×	360	8.9k
Bruce J. Roth United States	38	1.7k 0.4×	2.1k 0.5×	2.7k 1.0×	1.4k 0.9×	208 0.2×	124	5.8k
Didier Cupissol France	36	4.4k 0.9×	4.9k 1.3×	2.5k 0.9×	1.6k 1.0×	764 0.6×	160	8.9k

Countries citing papers authored by Sandrine Marréaud

Since Specialization

Citations

This map shows the geographic impact of Sandrine Marréaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandrine Marréaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandrine Marréaud more than expected).

Fields of papers citing papers by Sandrine Marréaud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandrine Marréaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandrine Marréaud. The network helps show where Sandrine Marréaud may publish in the future.

Co-authorship network of co-authors of Sandrine Marréaud

This figure shows the co-authorship network connecting the top 25 collaborators of Sandrine Marréaud. A scholar is included among the top collaborators of Sandrine Marréaud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandrine Marréaud. Sandrine Marréaud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yip, Desmond, John Zalcberg, Jean‐Yves Blay, et al.. (2025). Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial. British Journal of Cancer. 132(10). 897–904. 1 indexed citations

Litière, Saskia, Anouk Neven, Ian Judson, et al.. (2022). New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC – Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas. European Journal of Cancer. 174. 261–276. 7 indexed citations

Litière, Saskia, Anouk Neven, Ian Judson, et al.. (2021). Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas. European Journal of Cancer. 154. 253–268. 7 indexed citations

Wagner, Dorothea, Heike I. Grabsch, Murielle Mauer, et al.. (2019). EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer. 19(1). 494–494. 87 indexed citations

Schöffski, Patrick, Agnieszka Woźniak, Michael Leahy, et al.. (2018). The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’. European Journal of Cancer. 94. 156–167. 32 indexed citations

Tryfonidis, Konstantinos, Sandrine Marréaud, Hussein Khaled, et al.. (2017). Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. Breast Cancer Research and Treatment. 163(3). 507–515. 2 indexed citations

Casali, Paolo G., Axel Le Cesne, Andrés Poveda, et al.. (2017). Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial. Annals of Oncology. 28. v645–v645.

Schöffski, Patrick, Agnieszka Woźniak, Bernard Escudier, et al.. (2017). Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. European Journal of Cancer. 87. 147–163. 94 indexed citations

Bui-Nguyen, B., James E. Butrynski, Nicolas Penel, et al.. (2015). A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial. European Journal of Cancer. 51(10). 1312–1320. 59 indexed citations

10.

Fumoleau, P., Kevin M. Koch, Étienne Brain, et al.. (2014). A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). The Breast. 23(5). 663–669. 10 indexed citations

11.

Cesne, Axel Le, M. Ouali, Michael Leahy, et al.. (2014). Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Annals of Oncology. 25(12). 2425–2432. 118 indexed citations

12.

Frezza, Anna Maria, Charlotte Benson, Ian Judson, et al.. (2014). Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. PubMed. 4(1). 7–7. 41 indexed citations

13.

Brausi, Maurizio, Jorg R. Oddens, Richard Sylvester, et al.. (2013). Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG. European Urology. 65(1). 69–76. 244 indexed citations

14.

Bellmunt, Joaquim, Hans von der Maase, Graham M. Mead, et al.. (2012). Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987. Journal of Clinical Oncology. 30(10). 1107–1113. 324 indexed citations

15.

Wit, Ronald de, Iwona Skoneczna, Gedske Daugaard, et al.. (2012). Randomized Phase III Study Comparing Paclitaxel–Bleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell Cancer: Intergroup Study EORTC 30983. Journal of Clinical Oncology. 30(8). 792–799. 47 indexed citations

16.

Preusser, Matthias, Frank Winkler, Laurence Collette, et al.. (2012). Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. European Journal of Cancer. 48(18). 3439–3447. 37 indexed citations

17.

Santis, Maria De, Joaquim Bellmunt, Graham M. Mead, et al.. (2011). Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. Journal of Clinical Oncology. 30(2). 191–199. 523 indexed citations breakdown →

18.

Sleijfer, Stefan, Isabelle Ray‐Coquard, Zsuzsa Pápai, et al.. (2009). Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). Journal of Clinical Oncology. 27(19). 3126–3132. 535 indexed citations breakdown →

19.

Santis, Maria De, Joaquim Bellmunt, Graham M. Mead, et al.. (2009). Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy: Phase II—Results of EORTC Study 30986. Journal of Clinical Oncology. 27(33). 5634–5639. 123 indexed citations

20.

Ray‐Coquard, Isabelle, Axel Le Cesne, Jeremy Whelan, et al.. (2008). A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens. The Oncologist. 13(4). 467–473. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact